| Title : Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods - Henstra_2022_Front.Psychiatry_13_953686 |
| Author(s) : Henstra MJ , Feenstra TC , Kok RM , Spaans HP , van Exel E , Dols A , Oudega M , Vergouwen ACM , van der Loo A , Bet PM , Loer SA , Eikelenboom M , Sienaert P , Lambrichts S , Bouckaert F , Bosmans JE , van der Velde N , Beekman ATF , Stek ML , Rhebergen D |
| Ref : Front Psychiatry , 13 :953686 , 2022 |
| Abstract : Henstra_2022_Front.Psychiatry_13_953686 |
| ESTHER : Henstra_2022_Front.Psychiatry_13_953686 |
| PubMedSearch : Henstra_2022_Front.Psychiatry_13_953686 |
| PubMedID: 35911242 |
Henstra MJ, Feenstra TC, Kok RM, Spaans HP, van Exel E, Dols A, Oudega M, Vergouwen ACM, van der Loo A, Bet PM, Loer SA, Eikelenboom M, Sienaert P, Lambrichts S, Bouckaert F, Bosmans JE, van der Velde N, Beekman ATF, Stek ML, Rhebergen D (2022)
Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods
Front Psychiatry
13 :953686
Henstra MJ, Feenstra TC, Kok RM, Spaans HP, van Exel E, Dols A, Oudega M, Vergouwen ACM, van der Loo A, Bet PM, Loer SA, Eikelenboom M, Sienaert P, Lambrichts S, Bouckaert F, Bosmans JE, van der Velde N, Beekman ATF, Stek ML, Rhebergen D (2022)
Front Psychiatry
13 :953686